Granting Stock Options to Directors and Employees
First written in FY2018-Q3. 4 of 9 entries say "Advanced", first in FY2018. Latest entry: 2026-08-19.
- FY2025AchievedAnnual report
「Exercise period: 22 December 2022 to 21 December 2024」
Of the stock options approved in 2018, 39,400 shares were exercised and 13,600 shares expired, leaving no outstanding unexercised rights. The transition from stock options to restricted stock compensation was completed in practice. - FY2022AdvancedAnnual report
「The breakdown of the 74,000-share decrease in treasury shares is as follows: disposal of 74,000 treasury shares pursuant to a resolution of the Board of Directors dated 21 July 2021.」
Under the policy of transitioning from stock options to restricted stock compensation, the company disposed of 74,000 treasury shares as compensation in July 2021. - FY2021Expansion from stock options to restricted stock compensationAnnual report
「Separately from basic compensation, the limit on compensation for grants of restricted stock to directors, excluding outside directors, introduced in place of stock options, was approved at the 63rd Annual General Meeting of Shareholders held on 25 June 2019 at an annual amount of no more than ¥40 million, covering no more than 250,000 shares per year.」
In addition to the existing stock options, the company explicitly disclosed the transition to a restricted stock compensation plan for directors. - FY2019-Q1AdvancedAnnual report
「Categories and number of eligible persons: 8 directors of the company and 3 audit & supervisory board members. Number of stock acquisition rights: 196※. (Note 1) Class of shares underlying the stock acquisition rights: common shares. Number of shares: 39,200 (Note 1). Exercise period for the stock acquisition rights: 24 April 2022 to 23 April 2024.」
For the resolution dated 23 April 2018, the company granted 196 stock acquisition rights covering 39,200 shares to 8 directors and 3 audit & supervisory board members, with an exercise period from 24 April 2022 to 23 April 2024. - FY2018AdvancedAnnual report
「At the Annual General Meeting of Shareholders held on 22 June 2018, the company resolved, pursuant to the Companies Act, to issue stock acquisition rights without consideration as stock options to directors, audit & supervisory board members, and employees of the company and its subsidiaries, and to delegate to the Board of Directors the authority to determine the offering terms.」
In addition to the existing grants, the company resolved on 22 June 2018 to establish a framework for the free issuance of stock acquisition rights to directors, audit & supervisory board members, and employees. The limit was 1,600 rights, covering 160,000 shares. - FY2018-Q3First statedAnnual report
「Pursuant to this delegation, at a meeting of the Board of Directors held on 20 December 2017, the company resolved the terms of the offering and other matters concerning the solicitation of subscribers for the relevant stock acquisition rights. The rights were allocated to the eligible persons on 12 January 2018. Categories and number of eligible persons: 7 directors of the company's subsidiaries and 149 employees of the company and its subsidiaries. Number of stock acquisition rights: 604. Number of shares: 120,800. Exercise period for the stock acquisition rights: 21 December 2021 to 20 December 2023.」
The company allocated 604 stock acquisition rights covering 120,800 shares to 7 directors and 149 employees of the company and its subsidiaries. The exercise period was set from 21 December 2021 to 20 December 2023.